Michael Farzan, Ph.D.
Chair & Professor Of Department Of Immunology And Microbiology
About Michael Farzan
Additional Positions:
Professor and Chair, Department of Immunology and Microbiology
2020 – Current
·
The Scripps Research Institute
Professor and Co-chair, Department of Immunology and Microbiology
2017 – 2020
·
The Scripps Research Institute
Professor and Vice Chair, Department of Immunology and Microbial Science
2015 – 2017
·
The Scripps Research Institute
Professor, Department of Microbiology and Immunobiology
2012 – 2012
·
Harvard Medical School
Professor, Department of Infectious Diseases
2012 – 2015
·
The Scripps Research Institute
Associate Professor, Department of Microbiology and Immunobiology
2007 – 2012
·
Harvard Medical School
Assistant Professor, Department of Microbiology and Molecular Genetics
2005 – 2007
·
Harvard Medical School
Assistant Professor, Department of Medicine
2002 – 2004
·
Harvard Medical School
Instructor, Department of Pathology
1999 – 2002
·
Harvard Medical School
Post-Doctoral Fellow, Department of Pathology
1997 – 1999
·
Harvard Medical School
Graduate Student, Program in Immunology
1993 – 1997
·
Harvard Medical School
Accomplishments
Elected Fellow
2019
·
American Academy of Microbiology
NIDA Avant-Garde Award, "A safety switch for an effective HIV-1 vaccine"
2017-2022
·
—
NIAID MERIT Award, "Therapeutic uses of an enhanced form of CD4-Ig"
2016-2021
·
—
Founder
2015-2022
·
Emmune Inc.
Grand Challenges Award
2015-2019
·
Bill and Melinda Gates Foundation
Top NIAID Research Advances
2015
·
—
Chair, Florida Curriculum Committee
2014-2019
·
The Scripps Research Institute
Member
2010-2015
·
NIH Systems Biology Working Group (SBWG)
Steering Committee, Infectious Disease Initiative
2009-2014
·
Broad Institute
Member
2009-2013
·
NIH AIDS Molecular and Cellular Biology (AMCB) Study Section
Kavli Fellowship
2008
·
The Kavli Foundation and the National Academy of Sciences
Editorial Board
2007-2022
·
Journal of Virology
Section Editor for Viral Pathogenesis
2007-2016
·
PLoS Pathogens
Awarded
2007-2012
·
Burroughs Wellcome Fund Investigators in Pathogenesis Award
Awarded
2004
·
GlaxoSmithKline Drug Discovery and Developmental Research Award
Richard A. Smith Prize
2000
·
Dana-Farber Cancer Institute
Research Profile
Our laboratory focuses on entry processes of enveloped viruses and the various ways that the innate and adaptive immune responses inhibit these processes. We also apply our insights toward developing therapeutic strategies that enhance or supplement these immune responses. Our work can be divided into three categories: (1) biochemical studies of the HIV-1 entry process and its inhibition, (2) identification and characterization of obligate factors, including receptors, necessary for the entry of other enveloped viruses, and (3) identification and characterization of host restriction factors that inhibit early steps in the viral life cycle, in particular those of the IFITM family.
In addition to these scientific goals, we are developing a means of providing sustained, universal protection from HIV-1. Our most effective strategy uses adeno-associated virus (AAV) to express, eCD4-Ig, an exceptionally broad and potent HIV-1 entry inhibitor. We have shown that this strategy protects rhesus macaques from virus challenges greater than any human is likely to encounter, and thus it provides more effective protection than any conventional vaccine approach. To improve the safety of this approach, we are also developing regulatory switches that can dose or inactivate an AAV transgene.
Open Researcher and Contributor ID (ORCID)
0000-0002-2990-5319
Publications
2022
Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission
Science Advances.
8(2)
[DOI] 10.1126/sciadv.abj5666.
[PMID] 35020436.
2022
Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
SLAS discovery : advancing life sciences R & D.
27(1):8-19
[DOI] 10.1016/j.slasd.2021.10.012.
[PMID] 35058179.
2022
Mechanisms of SARS-CoV-2 entry into cells
Nature Reviews Molecular Cell Biology.
23(1):3-20
[DOI] 10.1038/s41580-021-00418-x.
[PMID] 34611326.
2022
Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire
Molecular Therapy.
30(1):184-197
[DOI] 10.1016/j.ymthe.2021.10.027.
[PMID] 34740791.
2021
A more efficient CRISPR-Cas12a variant derived from Lachnospiraceae bacterium MA2020
Molecular Therapy – Nucleic Acids.
24:40-53
[DOI] 10.1016/j.omtn.2021.02.012.
[PMID] 33738137.
2021
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent
Nature Structural & Molecular Biology.
28(2):202-209
[DOI] 10.1038/s41594-020-00549-3.
[PMID] 33432247.
2021
An Engineered Receptor-Binding Domain Improves the Immunogenicity of Multivalent SARS-CoV-2 Vaccines.
mBio.
12(3)
[DOI] 10.1128/mBio.00930-21.
[PMID] 33975938.
2021
Author Correction: IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in BÂ cells
Nature.
592(7852):E3-E3
[DOI] 10.1038/s41586-021-03388-4.
2021
Correction: Tickner, Z.J.; Farzan, M. Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors. Pharmaceuticals 2021, 14, 554.
Pharmaceuticals (Basel, Switzerland).
14(12)
[DOI] 10.3390/ph14121271.
[PMID] 34959739.
2021
Donor Anti-Spike Immunity is Related to Recipient Recovery and Can Predict the Efficacy of Convalescent Plasma Units.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2021.02.25.21252463.
[PMID] 33688667.
2021
Functional importance of the D614G mutation in the SARS-CoV-2 spike protein.
Biochemical and biophysical research communications.
538:108-115
[DOI] 10.1016/j.bbrc.2020.11.026.
[PMID] 33220921.
2021
How SARS-CoV-2 first adapted in humans.
Science (New York, N.Y.).
372(6541):466-467
[DOI] 10.1126/science.abi4711.
[PMID] 33926942.
2021
Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2
PLOS Pathogens.
17(1)
[DOI] 10.1371/journal.ppat.1009212.
[PMID] 33465165.
2021
In vitro affinity maturation of broader and more-potent variants of the HIV-1-neutralizing antibody CAP256-VRC26.25.
Proceedings of the National Academy of Sciences of the United States of America.
118(29)
[DOI] 10.1073/pnas.2106203118.
[PMID] 34261793.
2021
Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2
PLOS Pathogens.
17(4)
[DOI] 10.1371/journal.ppat.1009501.
[PMID] 33836016.
2021
Predicting the efficacy of COVID-19 convalescent plasma donor units with the Lumit Dx anti-receptor binding domain assay.
PloS one.
16(7)
[DOI] 10.1371/journal.pone.0253551.
[PMID] 34310603.
2021
Riboswitches for Controlled Expression of Therapeutic Transgenes Delivered by Adeno-Associated Viral Vectors.
Pharmaceuticals (Basel, Switzerland).
14(6)
[DOI] 10.3390/ph14060554.
[PMID] 34200913.
2020
A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies
mBio.
11(1)
[DOI] 10.1128/mbio.03080-19.
2020
A reversible RNA on-switch that controls gene expression of AAV-delivered therapeutics in vivo
Nature Biotechnology.
38(2):169-175
[DOI] 10.1038/s41587-019-0357-y.
[PMID] 31873216.
2020
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice.
Immunity.
53(4):724-732.e7
[DOI] 10.1016/j.immuni.2020.07.019.
[PMID] 32783919.
2020
A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.09.18.301952.
[PMID] 32995768.
2020
AAV vectors engineered to target insulin receptor greatly enhance intramuscular gene delivery.
Molecular therapy. Methods & clinical development.
19:496-506
[DOI] 10.1016/j.omtm.2020.11.004.
[PMID] 33313337.
2020
An engineered receptor-binding domain improves the immunogenicity of multivalent SARS-CoV-2 vaccines.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.11.18.388934.
[PMID] 33236008.
2020
High-Throughput Screening for Drugs That Inhibit Papain-Like Protease in SARS-CoV-2.
SLAS discovery : advancing life sciences R & D.
25(10):1152-1161
[DOI] 10.1177/2472555220963667.
[PMID] 33043784.
2020
IFITM3 functions as a PIP3 scaffold to amplify PI3K signalling in BÂ cells
Nature.
588(7838):491-497
[DOI] 10.1038/s41586-020-2884-6.
[PMID] 33149299.
2020
Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.06.29.178459.
[PMID] 32637954.
2020
SARS-CoV-2 and Three Related Coronaviruses Utilize Multiple ACE2 Orthologs and Are Potently Blocked by an Improved ACE2-Ig.
Journal of virology.
94(22)
[DOI] 10.1128/JVI.01283-20.
[PMID] 32847856.
2020
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
Nature Communications.
11(1)
[DOI] 10.1038/s41467-020-19808-4.
[PMID] 33243994.
2020
Selection of High-Affinity RNA Aptamers That Distinguish between Doxycycline and Tetracycline
Biochemistry.
59(37):3473-3486
[DOI] 10.1021/acs.biochem.0c00586.
[PMID] 32857495.
2020
The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity.
bioRxiv : the preprint server for biology.
[DOI] 10.1101/2020.06.12.148726.
[PMID] 32587973.
2019
A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies.
Journal of virology.
93(5)
[DOI] 10.1128/JVI.01653-18.
[PMID] 30541842.
2019
AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges
Science Translational Medicine.
11(502)
[DOI] 10.1126/scitranslmed.aau5409.
[PMID] 31341061.
2019
Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies.
Molecular therapy : the journal of the American Society of Gene Therapy.
27(3):650-660
[DOI] 10.1016/j.ymthe.2019.01.004.
[PMID] 30704961.
2019
Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET.
Nature.
568(7752):415-419
[DOI] 10.1038/s41586-019-1101-y.
[PMID] 30971821.
2019
Circumventing cellular immunity by miR142-mediated regulation sufficiently supports rAAV-delivered OVA expression without activating humoral immunity.
JCI insight.
5
[DOI] 10.1172/jci.insight.99052.
[PMID] 31112525.
2019
eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody.
Journal of virology.
93(14)
[DOI] 10.1128/JVI.00443-19.
[PMID] 31068428.
2019
Zika Virus-Immune Plasmas from Symptomatic and Asymptomatic Individuals Enhance Zika Pathogenesis in Adult and Pregnant Mice.
mBio.
10(4)
[DOI] 10.1128/mBio.00758-19.
[PMID] 31266863.
2018
Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence.
Molecular therapy : the journal of the American Society of Gene Therapy.
26(5):1277-1286
[DOI] 10.1016/j.ymthe.2018.02.021.
[PMID] 29567311.
2018
Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies
PLOS Pathogens.
14(8)
[DOI] 10.1371/journal.ppat.1007238.
[PMID] 30125330.
2018
eCD4-Ig Variants That More Potently Neutralize HIV-1.
Journal of virology.
92(12)
[DOI] 10.1128/JVI.02011-17.
[PMID] 29593050.
2018
HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
PloS one.
13(10)
[DOI] 10.1371/journal.pone.0206365.
[PMID] 30359435.
2017
Cpf1 proteins excise CRISPR RNAs from mRNA transcripts in mammalian cells.
Nature chemical biology.
13(8):839-841
[DOI] 10.1038/nchembio.2410.
[PMID] 28628097.
2017
eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients
PLOS Pathogens.
13(12)
[DOI] 10.1371/journal.ppat.1006786.
[PMID] 29253851.
2017
Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.
Current opinion in HIV and AIDS.
12(3):294-301
[DOI] 10.1097/COH.0000000000000367.
[PMID] 28422793.
2017
Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4.
Journal of virology.
91(18)
[DOI] 10.1128/JVI.00847-17.
[PMID] 28679752.
2016
Author response: Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells
.
[DOI] 10.7554/elife.18858.018.
2016
CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies.
Journal of virology.
90(17):7822-32
[DOI] 10.1128/JVI.00803-16.
[PMID] 27334589.
2016
Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.
Proceedings of the National Academy of Sciences of the United States of America.
113(24):E3413-22
[DOI] 10.1073/pnas.1606636113.
[PMID] 27247400.
2016
Rational design of aptazyme riboswitches for efficient control of gene expression in mammalian cells
eLife.
5
[DOI] 10.7554/elife.18858.
2016
The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic and Encephalitic Alphaviruses.
Journal of virology.
90(19):8780-94
[DOI] 10.1128/JVI.00655-16.
[PMID] 27440901.
2016
The Interferon-Stimulated Gene Ifitm3 Restricts West Nile Virus Infection and Pathogenesis.
Journal of virology.
90(18):8212-25
[DOI] 10.1128/JVI.00581-16.
[PMID] 27384652.
2015
AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges.
Nature.
519(7541):87-91
[DOI] 10.1038/nature14264.
[PMID] 25707797.
2015
Envelope Glycoprotein Internalization Protects Human and Simian Immunodeficiency Virus-Infected Cells from Antibody-Dependent Cell-Mediated Cytotoxicity.
Journal of virology.
89(20):10648-55
[DOI] 10.1128/JVI.01911-15.
[PMID] 26269175.
2015
Mechanism for Selective Synaptic Wiring of Rod Photoreceptors into the Retinal Circuitry and Its Role in Vision.
Neuron.
87(6):1248-1260
[DOI] 10.1016/j.neuron.2015.09.002.
[PMID] 26402607.
2015
Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.
mBio.
6(2)
[DOI] 10.1128/mBio.00296-15.
[PMID] 25900654.
2015
The Triggering Receptor Expressed on Myeloid Cells 2 Binds Apolipoprotein E.
The Journal of biological chemistry.
290(43):26033-42
[DOI] 10.1074/jbc.M115.677286.
[PMID] 26374897.
2015
Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.
Proceedings of the National Academy of Sciences of the United States of America.
112(47):14682-7
[DOI] 10.1073/pnas.1508095112.
[PMID] 26575624.
2014
A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120.
Journal of virology.
88(6):3353-8
[DOI] 10.1128/JVI.03800-13.
[PMID] 24390333.
2014
IFITM-Family Proteins: The Cell’s First Line of Antiviral Defense.
Annual review of virology.
1:261-283
[PMID] 25599080.
2014
IFITM3 polymorphism rs12252-C restricts influenza A viruses.
PloS one.
9(10)
[DOI] 10.1371/journal.pone.0110096.
[PMID] 25314048.
2014
The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus.
PloS one.
9(5)
[DOI] 10.1371/journal.pone.0096579.
[PMID] 24827144.
2014
UVRAG is required for virus entry through combinatorial interaction with the class C-Vps complex and SNAREs.
Proceedings of the National Academy of Sciences of the United States of America.
111(7):2716-21
[DOI] 10.1073/pnas.1320629111.
[PMID] 24550300.
2013
Direct expression and validation of phage-selected peptide variants in mammalian cells.
The Journal of biological chemistry.
288(26):18803-10
[DOI] 10.1074/jbc.M113.452839.
[PMID] 23667257.
2013
Dual host-virus arms races shape an essential housekeeping protein.
PLoS biology.
11(5)
[DOI] 10.1371/journal.pbio.1001571.
[PMID] 23723737.
2013
IFITM-2 and IFITM-3 but not IFITM-1 restrict Rift Valley fever virus.
Journal of virology.
87(15):8451-64
[DOI] 10.1128/JVI.03382-12.
[PMID] 23720721.
2013
Interferon-induced transmembrane protein 3 is a type II transmembrane protein.
The Journal of biological chemistry.
288(45):32184-32193
[DOI] 10.1074/jbc.M113.514356.
[PMID] 24067232.
2013
Lectin-dependent enhancement of Ebola virus infection via soluble and transmembrane C-type lectin receptors.
PloS one.
8(4)
[DOI] 10.1371/journal.pone.0060838.
[PMID] 23573288.
2013
The antiviral effector IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry.
Cell host & microbe.
13(4):452-64
[DOI] 10.1016/j.chom.2013.03.006.
[PMID] 23601107.
2013
The broad-spectrum antiviral functions of IFIT and IFITM proteins.
Nature reviews. Immunology.
13(1):46-57
[DOI] 10.1038/nri3344.
[PMID] 23237964.
2013
TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine.
PLoS pathogens.
9(3)
[DOI] 10.1371/journal.ppat.1003232.
[PMID] 23555248.
2012
An antibody recognizing the apical domain of human transferrin receptor 1 efficiently inhibits the entry of all new world hemorrhagic Fever arenaviruses.
Journal of virology.
86(7):4024-8
[DOI] 10.1128/JVI.06397-11.
[PMID] 22278244.
2012
Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants.
Journal of virology.
86(22):12417-21
[DOI] 10.1128/JVI.00967-12.
[PMID] 22933279.
2012
Evidence for ACE2-utilizing coronaviruses (CoVs) related to severe acute respiratory syndrome CoV in bats.
Journal of virology.
86(11):6350-3
[DOI] 10.1128/JVI.00311-12.
[PMID] 22438550.
2012
IFITM proteins restrict antibody-dependent enhancement of dengue virus infection.
PloS one.
7(3)
[DOI] 10.1371/journal.pone.0034508.
[PMID] 22479637.
2012
Ifitm3 limits the severity of acute influenza in mice.
PLoS pathogens.
8(9)
[DOI] 10.1371/journal.ppat.1002909.
[PMID] 22969429.
2011
A tyrosine-sulfated CCR5-mimetic peptide promotes conformational transitions in the HIV-1 envelope glycoprotein.
Journal of virology.
85(15):7563-71
[DOI] 10.1128/JVI.00630-11.
[PMID] 21613393.
2011
Association of membrane rafts and postsynaptic density: proteomics, biochemical, and ultrastructural analyses.
Journal of neurochemistry.
119(1):64-77
[DOI] 10.1111/j.1471-4159.2011.07404.x.
[PMID] 21797867.
2011
Distinct patterns of IFITM-mediated restriction of filoviruses, SARS coronavirus, and influenza A virus.
PLoS pathogens.
7(1)
[DOI] 10.1371/journal.ppat.1001258.
[PMID] 21253575.
2011
Ebolavirus delta-peptide immunoadhesins inhibit marburgvirus and ebolavirus cell entry.
Journal of virology.
85(17):8502-13
[DOI] 10.1128/JVI.02600-10.
[PMID] 21697477.
2011
Identification of a small-molecule entry inhibitor for filoviruses.
Journal of virology.
85(7):3106-19
[DOI] 10.1128/JVI.01456-10.
[PMID] 21270170.
2011
Transferrin receptor 1 in the zoonosis and pathogenesis of New World hemorrhagic fever arenaviruses.
Current opinion in microbiology.
14(4):476-82
[DOI] 10.1016/j.mib.2011.07.014.
[PMID] 21807555.
2010
Structural basis for receptor recognition by New World hemorrhagic fever arenaviruses.
Nature structural & molecular biology.
17(4):438-44
[DOI] 10.1038/nsmb.1772.
[PMID] 20208545.
2010
Sulfotyrosines of the Kaposi’s sarcoma-associated herpesvirus G protein-coupled receptor promote tumorigenesis through autocrine activation.
Journal of virology.
84(7):3351-61
[DOI] 10.1128/JVI.01939-09.
[PMID] 20106924.
2009
A New World primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1.
Journal of virology.
83(17):8771-80
[DOI] 10.1128/JVI.00112-09.
[PMID] 19553332.
2009
Chapter 7. Tyrosine sulfation of HIV-1 coreceptors and other chemokine receptors.
Methods in enzymology.
461:147-70
[DOI] 10.1016/S0076-6879(09)05407-X.
[PMID] 19480918.
2009
Host-species transferrin receptor 1 orthologs are cellular receptors for nonpathogenic new world clade B arenaviruses.
PLoS pathogens.
5(4)
[DOI] 10.1371/journal.ppat.1000358.
[PMID] 19343214.
2009
Identification of a new region of SARS-CoV S protein critical for viral entry.
Journal of molecular biology.
394(4):600-5
[DOI] 10.1016/j.jmb.2009.10.032.
[PMID] 19853613.
2009
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I.
Cell host & microbe.
5(5):439-49
[DOI] 10.1016/j.chom.2009.04.006.
[PMID] 19454348.
2009
Mutagenesis and evolution of sulfated antibodies using an expanded genetic code.
Biochemistry.
48(37):8891-8
[DOI] 10.1021/bi9011429.
[PMID] 19715291.
2009
The IFITM proteins mediate cellular resistance to influenza A H1N1 virus, West Nile virus, and dengue virus.
Cell.
139(7):1243-54
[DOI] 10.1016/j.cell.2009.12.017.
[PMID] 20064371.
2008
Evolution of a TRIM5-CypA splice isoform in old world monkeys.
PLoS pathogens.
4(2)
[DOI] 10.1371/journal.ppat.1000003.
[PMID] 18389077.
2008
Influenza A virus neuraminidase limits viral superinfection.
Journal of virology.
82(10):4834-43
[DOI] 10.1128/JVI.00079-08.
[PMID] 18321971.
2008
Protein evolution with an expanded genetic code.
Proceedings of the National Academy of Sciences of the United States of America.
105(46):17688-93
[DOI] 10.1073/pnas.0809543105.
[PMID] 19004806.
2008
Receptor determinants of zoonotic transmission of New World hemorrhagic fever arenaviruses.
Proceedings of the National Academy of Sciences of the United States of America.
105(7):2664-9
[DOI] 10.1073/pnas.0709254105.
[PMID] 18268337.
2007
Changes in the V3 region of gp120 contribute to unusually broad coreceptor usage of an HIV-1 isolate from a CCR5 Delta32 heterozygote.
Virology.
362(1):163-78
[PMID] 17239419.
2007
Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse.
Virology.
361(1):93-102
[PMID] 17161858.
2007
Palmitoylation of the cysteine-rich endodomain of the SARS-coronavirus spike glycoprotein is important for spike-mediated cell fusion.
Virology.
360(2):264-74
[PMID] 17134730.
2007
Severe acute respiratory syndrome coronavirus entry as a target of antiviral therapies.
Antiviral therapy.
12(4 Pt B):639-50
[PMID] 17944271.
2007
The S proteins of human coronavirus NL63 and severe acute respiratory syndrome coronavirus bind overlapping regions of ACE2.
Virology.
367(2):367-74
[PMID] 17631932.
2007
Transferrin receptor 1 is a cellular receptor for New World haemorrhagic fever arenaviruses.
Nature.
446(7131):92-6
[PMID] 17287727.
2006
A tyrosine-sulfated peptide derived from the heavy-chain CDR3 region of an HIV-1-neutralizing antibody binds gp120 and inhibits HIV-1 infection.
The Journal of biological chemistry.
281(39):28529-35
[PMID] 16849323.
2006
Animal origins of the severe acute respiratory syndrome coronavirus: insight from ACE2-S-protein interactions.
Journal of virology.
80(9):4211-9
[PMID] 16611880.
2006
Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals.
Journal of medical virology.
78(1):1-8
[PMID] 16299724.
2006
Conformational states of the severe acute respiratory syndrome coronavirus spike protein ectodomain.
Journal of virology.
80(14):6794-800
[PMID] 16809285.
2006
Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.
The Journal of biological chemistry.
281(23):15951-8
[PMID] 16595665.
2006
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
Journal of immunology (Baltimore, Md. : 1950).
176(10):6085-92
[PMID] 16670317.
2006
Infection of human airway epithelia by SARS coronavirus is associated with ACE2 expression and localization.
Advances in experimental medicine and biology.
581:479-84
[PMID] 17037581.
2006
Insights from the association of SARS-CoV S-protein with its receptor, ACE2.
Advances in experimental medicine and biology.
581:209-18
[PMID] 17037532.
2006
Interactions between SARS coronavirus and its receptor.
Advances in experimental medicine and biology.
581:229-34
[PMID] 17037534.
2006
SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells.
The Journal of biological chemistry.
281(6):3198-203
[PMID] 16339146.
2006
SARS-CoV, but not HCoV-NL63, utilizes cathepsins to infect cells: viral entry.
Advances in experimental medicine and biology.
581:335-8
[PMID] 17037556.
2006
Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R.
The Journal of biological chemistry.
281(45):34610-6
[PMID] 16954221.
2006
Tyrosine sulfate trapped by amber.
Nature biotechnology.
24(11):1361-2
[PMID] 17093482.
2005
A highly conserved arginine in gp120 governs HIV-1 binding to both syndecans and CCR5 via sulfated motifs.
The Journal of biological chemistry.
280(47):39493-504
[PMID] 16157597.
2005
ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia.
Journal of virology.
79(23):14614-21
[PMID] 16282461.
2005
An alternative conformation of the gp41 heptad repeat 1 region coiled coil exists in the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor.
Virology.
338(1):133-43
[PMID] 15950253.
2005
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants.
Journal of virology.
79(10):5900-6
[PMID] 15857975.
2005
Functional mimicry of a human immunodeficiency virus type 1 coreceptor by a neutralizing monoclonal antibody.
Journal of virology.
79(10):6068-77
[PMID] 15857992.
2005
Genetic analysis of the SARS-coronavirus spike glycoprotein functional domains involved in cell-surface expression and cell-to-cell fusion.
Virology.
341(2):215-30
[PMID] 16099010.
2005
JLK inhibitors: isocoumarin compounds as putative probes to selectively target the gamma-secretase pathway.
Current Alzheimer research.
2(3):327-34
[PMID] 15974898.
2005
Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion.
Molecular microbiology.
55(5):1423-34
[PMID] 15720551.
2005
Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2.
The EMBO journal.
24(8):1634-43
[PMID] 15791205.
2005
Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.
Journal of virology.
79(5):2678-88
[PMID] 15708987.
2005
Structure of SARS coronavirus spike receptor-binding domain complexed with receptor.
Science (New York, N.Y.).
309(5742):1864-8
[PMID] 16166518.
2005
Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC).
Molecular microbiology.
55(5):1413-22
[PMID] 15720550.
2004
A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2.
The Journal of biological chemistry.
279(5):3197-201
[PMID] 14670965.
2004
Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus.
Cellular and molecular life sciences : CMLS.
61(21):2738-43
[PMID] 15549175.
2004
CD4-induced T-20 binding to human immunodeficiency virus type 1 gp120 blocks interaction with the CXCR4 coreceptor.
Journal of virology.
78(10):5448-57
[PMID] 15113923.
2004
Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2.
Journal of virology.
78(20):11429-33
[PMID] 15452268.
2004
N-linked glycosylation in the CXCR4 N-terminus inhibits binding to HIV-1 envelope glycoproteins.
Virology.
324(1):140-50
[PMID] 15183061.
2004
Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association.
Proceedings of the National Academy of Sciences of the United States of America.
101(8):2536-41
[PMID] 14983044.
2004
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.
Biochemical and biophysical research communications.
324(2):773-81
[PMID] 15474494.
2004
Retroviruses pseudotyped with the severe acute respiratory syndrome coronavirus spike protein efficiently infect cells expressing angiotensin-converting enzyme 2.
Journal of virology.
78(19):10628-35
[PMID] 15367630.
2004
Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120.
Proceedings of the National Academy of Sciences of the United States of America.
101(9):2706-11
[PMID] 14981267.
2003
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.
Nature.
426(6965):450-4
[PMID] 14647384.
2003
JLK isocoumarin inhibitors: selective gamma-secretase inhibitors that do not interfere with notch pathway in vitro or in vivo.
Journal of neuroscience research.
74(3):370-7
[PMID] 14598313.
2003
Ligand-independent dimerization of CXCR4, a principal HIV-1 coreceptor.
The Journal of biological chemistry.
278(5):3378-85
[PMID] 12433920.
2003
Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120.
Cell.
114(2):161-70
[PMID] 12887918.
2002
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate.
Journal of virology.
76(12):6277-92
[PMID] 12021361.
2002
Stimulation of enveloped virus infection by beta-amyloid fibrils.
The Journal of biological chemistry.
277(38):35019-24
[PMID] 12119288.
2002
The role of post-translational modifications of the CXCR4 amino terminus in stromal-derived factor 1 alpha association and HIV-1 entry.
The Journal of biological chemistry.
277(33):29484-9
[PMID] 12034737.
2002
Tyrosine-sulfated peptides functionally reconstitute a CCR5 variant lacking a critical amino-terminal region.
The Journal of biological chemistry.
277(43):40397-402
[PMID] 12183462.
2001
Human Mast cell progenitors can be infected by macrophagetropic human immunodeficiency virus type 1 and retain virus with maturation in vitro.
Journal of virology.
75(22):10808-14
[PMID] 11602722.
2001
Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines.
The Journal of experimental medicine.
194(11):1661-73
[PMID] 11733580.
2001
Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.
The Journal of experimental medicine.
193(9):1059-66
[PMID] 11342590.
2000
A tyrosine-sulfated peptide based on the N terminus of CCR5 interacts with a CD4-enhanced epitope of the HIV-1 gp120 envelope glycoprotein and inhibits HIV-1 entry.
The Journal of biological chemistry.
275(43):33516-21
[PMID] 10938094.
2000
Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.
Journal of virology.
74(24):11972-6
[PMID] 11090199.
2000
BACE2, a beta -secretase homolog, cleaves at the beta site and within the amyloid-beta region of the amyloid-beta precursor protein.
Proceedings of the National Academy of Sciences of the United States of America.
97(17):9712-7
[PMID] 10931940.
2000
Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins.
Journal of virology.
74(12):5716-25
[PMID] 10823881.
2000
Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
Journal of virology.
74(10):4746-54
[PMID] 10775613.
2000
Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5.
Nature biotechnology.
18(6):649-54
[PMID] 10835604.
1999
Adaptation of a CCR5-using, primary human immunodeficiency virus type 1 isolate for CD4-independent replication.
Journal of virology.
73(10):8120-6
[PMID] 10482561.
1999
Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor.
The Journal of biological chemistry.
274(40):28745-50
[PMID] 10497246.
1999
Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry.
Cell.
96(5):667-76
[PMID] 10089882.
1998
A tyrosine-rich region in the N terminus of CCR5 is important for human immunodeficiency virus type 1 entry and mediates an association between gp120 and CCR5.
Journal of virology.
72(2):1160-4
[PMID] 9445013.
1998
Expansion by self antigen is necessary for the induction of experimental autoimmune encephalomyelitis by T cells primed with a cross-reactive environmental antigen.
Journal of immunology (Baltimore, Md. : 1950).
161(7):3307-14
[PMID] 9759846.
1998
Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
Journal of virology.
72(9):7620-5
[PMID] 9696864.
1998
Structural interactions between chemokine receptors, gp120 Env and CD4.
Seminars in immunology.
10(3):249-57
[PMID] 9653051.
1998
The bis-azo compound FP-21399 inhibits HIV-1 replication by preventing viral entry.
Virology.
244(2):530-41
[PMID] 9601521.
1998
The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1.
Journal of virology.
72(7):6113-8
[PMID] 9621075.
1998
Use of murine CXCR-4 as a second receptor by some T-cell-tropic human immunodeficiency viruses.
Journal of virology.
72(2):1652-6
[PMID] 9445072.
1997
CCR3 and CCR5 are co-receptors for HIV-1 infection of microglia.
Nature.
385(6617):645-9
[PMID] 9024664.
1997
CD4-independent binding of SIV gp120 to rhesus CCR5.
Science (New York, N.Y.).
278(5342):1470-3
[PMID] 9367961.
1997
HIV-1 entry and macrophage inflammatory protein-1beta-mediated signaling are independent functions of the chemokine receptor CCR5.
The Journal of biological chemistry.
272(11):6854-7
[PMID] 9054370.
1997
Structure-based mutagenesis of the catalytic domain of human immunodeficiency virus type 1 integrase.
Journal of virology.
71(5):3507-14
[PMID] 9094622.
1997
Two orphan seven-transmembrane segment receptors which are expressed in CD4-positive cells support simian immunodeficiency virus infection.
The Journal of experimental medicine.
186(3):405-11
[PMID] 9236192.
1997
Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.
Journal of virology.
71(3):2522-7
[PMID] 9032394.
1996
The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates.
Cell.
85(7):1135-48
[PMID] 8674119.
1996
The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry.
Nature.
382(6594):829-33
[PMID] 8752280.
Anticipating future SARS-CoV-2 variants of concern through ab initio quantum mechanical modeling
.
[DOI] 10.1101/2021.11.25.470044.
Investigating the mutational landscape of the SARS-CoV-2 Omicron variant via ab initio quantum mechanical modeling
.
[DOI] 10.1101/2021.12.01.470748.
The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement
.
[DOI] 10.1101/2020.04.10.036418.
Education
Ph.D. in Immunology
1997
·
Harvard Medical School
A.B. Government
1984
·
Harvard College
Contact Details
Phones:
- Business:
- (561) 228-2000
Emails:
- Business:
- michael.farzan@ufl.edu
Addresses:
- Business Mailing:
-
120 SCRIPPS WAY
JUPITER FL 33458